share_log

Allarity Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(14.7%),Streeterville Management LLC(14.7%), etc.

Allarity Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Streeterville Capital LLC(14.7%),Streeterville Management LLC(14.7%), etc.

Allarity Therapeutics | SC 13G:超過5%持股股東披露文件-Streeterville Capital LLC(14.7%),Streeterville Management LLC(14.7%)等
美股SEC公告 ·  08/29 16:01

Moomoo AI 已提取核心訊息

Streeterville Capital LLC, along with Streeterville Management LLC and John M. Fife, have filed a Schedule 13G with the SEC, indicating a significant ownership stake in Allarity Therapeutics Inc. The filing, dated August 19, 2024, reports that Streeterville Capital LLC directly owns 8,999,800 shares of Allarity Therapeutics' common stock, representing 14.7% of the company's class of securities. John M. Fife, a U.S. citizen, is identified as the person with the authority to receive notices and communications regarding this ownership. The shares provide Streeterville Capital LLC with sole voting power and sole dispositive power over 2,114,737 shares. The filing asserts that the securities were acquired in the ordinary course of business and not with the purpose of changing or influencing the control of the issuer.
Streeterville Capital LLC, along with Streeterville Management LLC and John M. Fife, have filed a Schedule 13G with the SEC, indicating a significant ownership stake in Allarity Therapeutics Inc. The filing, dated August 19, 2024, reports that Streeterville Capital LLC directly owns 8,999,800 shares of Allarity Therapeutics' common stock, representing 14.7% of the company's class of securities. John M. Fife, a U.S. citizen, is identified as the person with the authority to receive notices and communications regarding this ownership. The shares provide Streeterville Capital LLC with sole voting power and sole dispositive power over 2,114,737 shares. The filing asserts that the securities were acquired in the ordinary course of business and not with the purpose of changing or influencing the control of the issuer.
Streeterville Capital LLC,以及Streeterville Management LLC和約翰·Fife先生,已向SEC提交了一份13G表,表明在Allarity Therapeutics Inc.擁有重要的所有權股份。報告日期爲2024年8月19日,顯示Streeterville Capital LLC直接持有Allarity Therapeutics的普通股8,999,800股,佔公司證券類別的14.7%。約翰·Fife先生,一位美國公民,被確定爲接收有關該持股的通知和通訊的授權人。這些股份授予Streeterville Capital LLC對2,114,737股的唯一投票權和唯一處置權。報告聲稱這些證券是在業務日常運作的過程中獲得的,並非出於改變或影響發行人控制權的目的。
Streeterville Capital LLC,以及Streeterville Management LLC和約翰·Fife先生,已向SEC提交了一份13G表,表明在Allarity Therapeutics Inc.擁有重要的所有權股份。報告日期爲2024年8月19日,顯示Streeterville Capital LLC直接持有Allarity Therapeutics的普通股8,999,800股,佔公司證券類別的14.7%。約翰·Fife先生,一位美國公民,被確定爲接收有關該持股的通知和通訊的授權人。這些股份授予Streeterville Capital LLC對2,114,737股的唯一投票權和唯一處置權。報告聲稱這些證券是在業務日常運作的過程中獲得的,並非出於改變或影響發行人控制權的目的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息